Evaluation of a Standardized Strategy for Uveitis Etiological Diagnosis (ULISSE)

May 23, 2019 updated by: Hospices Civils de Lyon

Uveitis: Medico-economical and Clinical Evaluation of a Standardized Strategy for an Etiological Diagnosis

The Uveitis, the inflammation of the uvea, is a rare disease with an incidence of 52/100,000 inhabitants per year and a prevalence of 115 / 100,000 inhabitants per year.

The causes of uveitis are numerous and include infectious diseases, systemic and neurological diseases, ophthalmic entities, neoplasia, and drug-related reactions. The etiological diagnosis is important both for prognosis and therapeutics.

However, clinical evaluations to establish etiological diagnosis are not standardized. Some authors suggest a minimalist examination, common to all kinds of uveitis. On the other hand, others propose an evaluation guided by the anatomo-clinical type of uveitis.

We conducted a retrospective study to assess the contribution of complementary examinations to etiological determination. In this study, we found that most patients benefited from a wide paraclinical evaluation compared to what is usually described in the literature. Complementary examinations were mostly systematic, without any clinical or ophthalmological elements of orientation. This study highlighted the lack of contribution of some examinations.

Using these results, and the literature analysis, we designed a diagnostic algorithm adapted to the anatomo-clinical type of uveitis.

Moreover, we found that the average cost per patient was estimated at €290.51 with the algorithm compared to €560.83 without it.

We would like to carry out a new study to estimate the efficiency as well as the medico-economic impact of the use of a standardized strategy for the etiological diagnosis of uveitis, compared with a free strategy.

Hypothesis:

  • The standardized strategy for the diagnostic of uveitis is at least as efficient as the free one, and costs half as much.
  • The examinations prescribed, except for those from the standardized strategy, do not contribute to etiological determination.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

905

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lyon, France, 69004
        • Service de Médecine Interne, Hospices Civils de Lyon (HCL)-Hôpital de la Croix Rousse

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Uveitis
  • Patient consulting one of the study's sites
  • Age > 18 years old
  • Affiliation to the French national health insurance program
  • Patient agreeing to participate in the study

Exclusion Criteria:

  • Positive HIV serology
  • Postsurgical or posttraumatic uveitis or endophthalmitis
  • Toxoplasmic uveitis
  • Pathology likely to be the cause of the known uveitis
  • Ophthalmic entities only diagnosed by the ophthalmic examination
  • Age < 18 years old
  • Patient under law protection or guardianship
  • Pregnant women or those planning to be pregnant during the study
  • Severe uveitis (VA < 20/200) with retinal vascularitis requiring an emergency treatment and assessment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Free strategy
Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
Other Names:
  • Procedure or strategy leading to the etiological diagnosis of the uveitis.
Experimental: Experimental strategy
Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The primary outcome is the percentage of patients having an etiological diagnosis 6 months after the beginning of the study for both strategies.
Time Frame: 6 months
Note: Only diagnoses made at the end of the standardized strategy will be numbered in this arm of the study; all diagnoses made after by the free authorized examinations in this same arm will lead to standardized strategy failure.
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical criteria concerning the standardized strategy
Time Frame: 6 months
  • Percentage of patients having an established etiological diagnosis at the end of the first diagnostic stage and at the end of the second diagnostic stage. (Second or third-line assessment).
  • Ratio of the standardized strategy's first stage examinations having contributed to the etiological diagnosis.
  • Ratio of the standardized strategy's second stage examinations, directed by the anatomo-clinical type of the uveitis (Second or third-line assessment) having contributed to an etiological diagnosis.
  • Ratio of free complementary examinations having contributed to an etiological diagnosis.
6 months
Clinical criteria concerning the free strategy
Time Frame: 6 months
  • Description and ratio of the examinations that have not allowed the doctor to make an etiological diagnosis.
  • Description and ratio of the complementary examinations not included in the standardized strategy.
6 months
The average cost of economic criteria for each strategy.
Time Frame: 12 months
  • For each patient: The standardized strategy's average cost of diagnosis distinguishing between first diagnostic stage costs and second diagnostic stage costs (made up of the second or third-line assessment directed by the anotomo-clinical type of the uveitis).
  • Average cost of the complementary examinations not included in the standardized strategy but allowed at the end of it (subsequent free assessment).
  • Average cost for each patient of the whole free strategy.
12 months
Quality of life criteria
Time Frame: : 6 months

- Quality of life, estimated with the standard quality of life questionnaire (SF-36) and the one specific to ophthalmology (NEI VFQ-25), will be compared between these groups:

  1. Uveitis diagnosis versus no diagnosis
  2. Free strategy versus standardized strategy.
: 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2010

Primary Completion (Actual)

July 1, 2014

Study Completion (Actual)

July 1, 2014

Study Registration Dates

First Submitted

July 12, 2010

First Submitted That Met QC Criteria

July 13, 2010

First Posted (Estimate)

July 14, 2010

Study Record Updates

Last Update Posted (Actual)

May 28, 2019

Last Update Submitted That Met QC Criteria

May 23, 2019

Last Verified

August 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2009.566/19

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Uveitis

Clinical Trials on Free strategy

3
Subscribe